Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 231 pages

Showing 151 - 200


issues in oncology
skin cancer
issues in oncology

Inherited Genetic Markers May Predict Melanoma Survival and Help Plot Course of Disease

At NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, researchers have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual’s survival and determine which patients require closer monitoring in the years...

skin cancer

Pregnancy-Associated Melanoma Is Linked With Higher Death Rates

Melanoma is on the rise in women of childbearing age. Those at the greatest risk, according to new Cleveland Clinic research, are women younger than 50 who are pregnant or have recently been pregnant. After adjusting for age, tumor location, and stage, researchers from Cleveland Clinic's...

palliative care
skin cancer
issues in oncology

Blood Test That Monitors ctDNA Better Than the Standard in Tracking Metastatic Melanoma

Physicians treating patients with metastatic melanoma may soon have a superior tool in their efforts to closely track the disease. A new study shows that a blood test that monitors blood levels of DNA fragments from dead cancer cells does a better job than the current standard test at tracking the...

skin cancer

Ocular Melanoma Research Fellowship Opportunity Announced

The American Association for Cancer Research (AACR) and the Ocular Melanoma Foundation (OMF) are pleased to announce a new partnership to provide a grant opportunity for researchers focused on ocular melanoma, which is diagnosed in approximately 2,000 adults in the United States each year....

skin cancer

May Is National Skin Cancer Awareness Month

According to the Skin Cancer Foundation, more than 3.5 million cases of skin cancer are diagnosed each year, with the incidences of skin cancer outnumbering all cases of breast, colon, lung, and prostate cancers combined. Of the three most common types of skin cancer—basal cell carcinoma, squamous...

skin cancer

FDA Expands Pembrolizumab Label to Include Approval in Initial Treatment of Unresectable or Metastatic Melanoma

On December 18, 2015, the U.S. Food and Drug Administration (FDA) expanded the pembrolizumab (Keytruda) label to include approval of the drug for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or...

skin cancer

FDA Approves Single-Agent Nivolumab for Previously Untreated BRAF Wild-Type Advanced Melanoma

The U.S. Food and Drug Administration (FDA) today approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Clinical Trial Results The approval is based on data...

kidney cancer
lung cancer
skin cancer
lymphoma
kidney cancer
head and neck cancer

Kidney Failure and Its Treatment May Impact Cancer Risk

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published by Yanik et al in the Journal of the American Society of Nephrology, suggest the need for persistent cancer...

skin cancer

FDA Approves Cobimetinib in Combination With Vemurafenib for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) approved cobimetinib (Cotellic) to be used in combination with vemurafenib (Zelboraf) to treat metastatic or unresectable melanoma, with the BRAF V600E or V600K mutation. “As we continue to advance our knowledge of tumor biology, we have...

skin cancer

FDA Approves Adjuvant Ipilimumab to Reduce the Risk of Melanoma Returning After Surgery

The U.S. Food and Drug Administration has expanded the approved use of ipilimumab (Yervoy) to include a new use as adjuvant therapy for patients who have cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm and have undergone complete resection, including total...

issues in oncology
skin cancer
issues in oncology

Newly Discovered Tumor-Suppressor Gene Affects Melanoma Survival

Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true drivers of cancer. A new study published by Arafeh et al in Nature Genetics, a Weizmann Institute of Science team has revealed one of the drivers of a particularly deadly subset of melanomas that...

skin cancer

FDA Approves Talimogene Laherparepvec for Unresectable Recurrent Melanoma

The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma...

skin cancer

ASTRO 2015: Subset of Patients With Metastatic Melanoma Achieves Clinical Benefit From Combination of Immunotherapy and Radiation Therapy

Immunotherapy combined with palliative radiation therapy for a subset of patients with metastatic melanoma reduces the growth and spread of the cancer, according to research presented by Hiniker et al (Abstract 215) on October 20, 2015 at the American Society for Radiation Oncology’s...

skin cancer
issues in oncology

More Than 11 Moles on the Arm May Indicate Higher Risk of Melanoma

Researchers at King's College London have investigated a new method that could be used by general practitioners to quickly determine the number of moles on the entire body by counting the number found on a smaller “proxy” body area, such as an arm. These findings were published by...

lung cancer
skin cancer

Antioxidants May Increase the Rate of Metastasis, Protect Existing Tumors in Malignant Melanoma

Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice. The results reinforce previous findings that antioxidants hasten the progression of lung cancer. According to Martin Bergö, PhD, people with cancer or an elevated risk of...

skin cancer

Surgical Resection Prolongs Survival for Patients Whose Melanoma Has Spread to the Abdomen

Surgical removal of melanoma that has metastasized to the abdomen appears to help patients live more than twice as long as those who receive only medical therapy, according to study results presented at the 2015 Clinical Congress of the American College of Surgeons. In more than 1,600 patients...

skin cancer

ECC 2015: Combination of Dabrafenib and Trametinib Superior to Vemurafenib Alone in Advanced Melanoma: Results of the COMBI-v Trial

The latest results from a trial of a combination of two targeted therapies (dabrafenib [Tafinlar] and trametinib [Mekinist]) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with vemurafenib (Zelboraf) alone. Caroline...

skin cancer

FDA Grants Accelerated Approval to Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type, Unresectable, or Metastatic Melanoma

On September 30, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of patients with BRAF V600 wild-type, unresectable, or metastatic melanoma. The FDA is scheduled to make a decision on ...

skin cancer
skin cancer
issues in oncology

Unprecedented Number of Mutations Identified in Rare Melanoma

A rare form of skin cancer known as desmoplasmic melanoma may possess the highest burden of gene mutations of any cancer, suggesting that immunotherapy may be a promising approach for treatment, according to an international team led by University of California San Francisco (UCSF) scientists. One...

skin cancer
issues in oncology
survivorship
issues in oncology
issues in oncology

Antifungal Agent Increases Risk of Cutaneous Squamous Cell Carcinoma in Some Lung Transplant Recipients

Voriconazole, commonly used to prevent and treat fungal infections in lung transplant recipients, significantly increases the risk for cutaneous squamous cell carcinoma in this population, according to a new study by University of California San Francisco researchers. The team recommends physicians ...

issues in oncology
skin cancer
issues in oncology

New Genetic Mutation Leading to Protein Repression Identified in Melanoma Cancer Cells

There is strong evidence that the protein complex APC/C may function as a tumor suppressor in multiple cancers including lymphoma, colorectal cancer, breast cancer, and now, melanoma. A new study has revealed that a genetic mutation leading to repression of a specific protein, Cdh1, which interacts ...

skin cancer

Pembrolizumab Treatment May Cause Immune Cells to Express Markers of Reinvigoration

Treating patients with metastatic melanoma with the immunotherapy drug pembrolizumab (Keytruda) caused immune cells called CD8-positive T cells in the patient’s blood to express markers of reinvigoration, according to data being presented at the CRI-CIMT-EATI-AACR International Cancer...

issues in oncology
skin cancer

Frequency of Certain Immune Cells in Blood May Predict Response to Pembrolizumab in Metastatic Melanoma

Among patients with metastatic melanoma treated with the immunotherapy drug pembrolizumab (Keytruda), those whose cancer responded to the treatment had a higher frequency of T cells that were positive for the proteins CD8, PD-1, and Bim (CD8+PD-1+Bim+ T cells) in blood samples taken immediately...

skin cancer

Immune System–Boosting Agent May Reduce Early-Stage Melanoma Recurrences

Among patients with clinically stage I or stage II melanoma, those treated with the immune system–boosting agent CpG-B were less likely to experience recurrence of their disease than those who received placebo, according to results from two randomized, placebo-controlled phase II clinical...

skin cancer
issues in oncology

Patients With Fewer Than 50 Moles May Be at Risk for More Aggressive Melanoma

People with more than 50 moles have an increased risk of developing melanoma, but those with fewer than 50 moles should still be alert for this disease. In fact, according to new research presented at the American Academy of Dermatology’s 2015 Summer Academy Meeting in New York, those with...

skin cancer

Organ Transplant Recipients May Be More Likely to Develop Aggressive Melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant and three times more likely to die of the skin cancer, suggested new research by a multi-institutional team. The findings, reported by Robbins et al in the Journal of Investigative...

palliative care
skin cancer

Combining Interleukin-2 With Imiquimod and Topical Retinoid Therapy May Be Effective Against Cutaneous Metastatic Melanoma

A novel combination therapy appears to be effective in treating patients with melanoma skin metastases, according to new research from the University of California (UC) Davis. Led by Emanual Maverakis, MD, of the UC Davis Department of Dermatology, the research found that interleukin-2...

skin cancer
skin cancer
issues in oncology

Key Genetic Factor in Cell Proliferation in Moles Identified

Scientists have known for years that a mutation in the BRAF gene makes moles start to grow but until now have not understood why they sometimes do not become cancerous. Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that...

skin cancer

FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...

cns cancers
gynecologic cancers
colorectal cancer
leukemia
lymphoma
skin cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers

A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...

issues in oncology
skin cancer
issues in oncology

Mapping Genetic Mutations in Cutaneous Melanoma

Researchers have a significantly better understanding of the genetic alterations found in cutaneous melanoma as part of a multi-institution, international effort of The Cancer Genome Atlas (TCGA). The study, published in Cell, refined and revealed new molecular subgroups of patients who could...

skin cancer

ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases

For patients with melanoma and micrometastases, as shown by positive sentinel lymph node biopsy, complete lymph node dissection did not improve survival, according to results of a randomized study presented at the 2015 ASCO Annual Meeting (Abstract LBA9002). “This is the first study which...

skin cancer

ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma

A randomized phase III trial among patients with previously untreated melanoma found that initial therapy with nivolumab (Opdivo) alone more than doubled the median progression-free survival compared with ipilimumab (Yervoy) alone (6.9 vs 2.9 months), and the benefit was even greater when the two...

skin cancer

ASCO 2015: Melanoma Rates Dramatically Increasing in Children and Young Adults

The incidence of melanoma has increased by more than 250% among children, adolescents, and young adults since 1973, according to research to be presented by Roswell Park Cancer Institute (RPCI) on June 1 at the 2015 ASCO Annual Meeting (Abstract 9058) in Chicago. The research has been recognized...

skin cancer
issues in oncology

ASCO 2015: Oral Vitamin Reduces Risk of Common Nonmelanoma Skin Cancers in High-Risk Patients

The Australian ONTRAC trial showed that a form of vitamin B3 called nicotinamide significantly reduced the rates of new skin cancers in people at high risk of the disease. Taken as a twice-daily pill, nicotinamide reduced the incidence of new nonmelanoma skin cancers by 23%. These findings were...

skin cancer

FDA Accepts Supplemental Biologics License Application for Nivolumab in Patients With Previously Untreated Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has accepted for filing and review Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted...

palliative care
skin cancer

AACR 2015: Combining Two Investigational Immunotherapy Drugs Safe, With Early Signs of Effectiveness

Combining the immunostimulatory anti-CD40 monoclonal antibody CP-870,893 with the immune checkpoint inhibitor tremelimumab was found to be safe, with clinical evidence of response in patients with advanced melanoma, according to phase I clinical trial data presented at the AACR Annual Meeting 2015, ...

palliative care
skin cancer

AACR 2015: Improved Responses With Ipilimumab-Nivolumab Combination vs Ipilimumab Alone in Advanced Melanoma

Giving the two immunotherapies ipilimumab (Yervoy) and nivolumab (Opdivo) simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment, according to phase II clinical trial data presented at the AACR Annual Meeting 2015,...

skin cancer

AACR 2015: New Immunotherapy Yields Long-Lasting Responses in Some Patients With Advanced Melanoma

A first-in-class immunotherapy called IMCgp100 yielded durable responses in patients with advanced cutaneous melanoma and those with advanced ocular melanoma, according to data from a phase I/IIa clinical trial presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract ...

skin cancer

AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial

In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...

skin cancer
issues in oncology
issues in oncology

Study Shows Lack of RNA Editing Leads to Melanoma Growth and Metastasis

In a new study reported by Shoshan et al in Nature Cell Biology, researchers at The University of Texas MD Anderson Cancer Center established a link between melanoma and lack of RNA editing, which leads to tumor growth and progression through manipulation of proteins. Study Findings Study lead...

skin cancer

FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a...

skin cancer

FDA Approves Nivolumab for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab...

breast cancer
skin cancer

FDA Approves Expanded Use of Tilmanocept for Lymphatic Mapping in Solid Tumors

The U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application for the expanded use of technetium 99m tilmanocept (Lymphoseek Injection) for lymphatic mapping in solid tumors and for adding sentinel lymph node detection for breast cancer and melanoma to the approved...

skin cancer

ESMO 2014: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma

The monoclonal antibody nivolumab achieved superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab (Yervoy), according to preliminary data from a phase III trial presented at the ESMO 2014...

skin cancer

FDA Approves Pembrolizumab for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to the anti–PD-1 antibody pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Pembrolizumab is intended for use following...

skin cancer

Surgical Treatment for Metastatic Melanoma of the Liver Increases Overall Survival in Select Group of Patients

Surgical resection markedly improved survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the Journal of the American College of Surgeons. These results mark a departure for melanoma, which is most often...

issues in oncology
skin cancer

Biomarker Identifies Melanoma Patients Who May Respond to Immunotherapy MK-3475

Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego. When the protein...

skin cancer
kidney cancer

Antibody Could Be Used to Target Tumor-Enhancing Protein, Study Shows

In a phase I study published in PLOS ONE, treating patients with advanced melanoma and kidney cancer with an antibody that targets a tumor-enhancing protein was found to have an acceptable safety profile and showed preliminary evidence of antitumor activity. The findings by Morris et al shed light...

skin cancer

Biomarker May Predict Response to Ipilimumab in Advanced Melanoma

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab (Yervoy), according to a study by Yuan et al published in Cancer Immunology Research....

Advertisement

Advertisement



;
Advertisement